Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip
A Single-arm, Open-label Study to Evaluate a Procedure for Intra-articular (IA) Injection of FX006 in Patients With Osteoarthritis (OA) of the Hip
Sponsor: Pacira Pharmaceuticals, Inc
Listed as NCT04065074, this PHASE2 trial focuses on Osteoarthritis, Hip and remains completed. Sponsored by Pacira Pharmaceuticals, Inc, it has been updated 9 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2022 — Feb 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Feb 2022 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2019 — Dec 2019 [monthly]
Recruiting PHASE2
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pacira Pharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .